Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP.
Herein, alkenylpiperidine and alkynylpiperidine moieties were introduced into the left wing of DAPYs (diarylpyrimidines) to explore the new site of the NNIBP (non-nucleoside inhibitor binding pocket) protein-solvent interface region via the structure-based drug design strategy. All the synthesized compounds displayed nanomolar to submicromolar activity against WT (wild-type) HIV-1. Among all, compound FT1 (EC50 = 19 nM) was found to be the most active molecule, which is better than NVP (EC50 = 0.10 μM). In addition, most of the compounds displayed micromolar activity against K103N and E138K mutant strains, while FT1 (EC50(K103N) = 50 nM, EC50(E138K) = 0.19 µM) still has the most effective activity. The molecular dynamics simulation studies revealed that the presence of pyridine moiety of FT1 was essential and played a significant role in its binding with RT (reverse transcriptase).
['Zhang|Tao|T|', 'Zhou|Zhongxia|Z|', 'Zalloum|Waleed A|WA|', 'Wang|Zhao|Z|', 'Fu|Zhipeng|Z|', 'Cherukupalli|Srinivasulu|S|', 'Feng|Da|D|', 'Sun|Yanying|Y|', 'Gao|Shenghua|S|', 'De Clercq|Erik|E|', 'Pannecouque|Christophe|C|', 'Kang|Dongwei|D|', 'Zhan|Peng|P|', 'Liu|Xinyong|X|']
HIV-1 NNRTIs DAPYs Structure-based drug design Reverse transcriptase